Pharmaceutical Executive March 6, 2024
Mike Hollan

Heavey discusses how the industry can avoid having efforts to accelerate discovery and development be hampered by manufacturing concerns.

For the pharmaceutical industry, the ability to produce drugs is just as important as the ability to develop new drugs. It doesn’t matter what drugs get developed if the industry can’t produce them to match the demand. Barry Heavey, supply chain lead at Accenture, spoke with Pharmaceutical Executive about how digital tools can help the manufacturing side keep up with the development side.

Pharmaceutical Executive: What would cause efforts to accelerate discovery and development to be hampered by clinical/commercial manufacturing?
Barry Heavey: New molecules moving quickly from discovery through clinical trial to launch may be difficult to manufacture at the pace required....

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Interview / Q&A, Pharma, Pharma / Biotech, Supply Chain, Technology, Trends
FTC pauses PBM litigation in win for Caremark, Express Scripts, Optum Rx
Pharma Dodges The Tariff Bullet — But For How Long?
Noom, LillyDirect pharmacy provider partner to increase access to Zepbound
Robots can aid hospital pharmacies in safer and more sustainable cancer drug preparation
PBM Private Labeling Boosts Biosimilars, Raises Concerns

Share This Article